Autoantigen signalling through chemokine receptors

Current Opinion in Rheumatology

Volumn 18, Issue 6, 2006, Pages 642-646

  Howard, O M Zack ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Autoantigen; Autoimmune; Chemokine; Chemokine receptor; Dendritic cells

Indexed keywords

AUTOANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST;

ANTIGEN FUNCTION; ANTIGEN STRUCTURE; AUTOIMMUNE DISEASE; CHEMOTAXIS; DENDRITIC CELL; DOWN REGULATION; DRUG TARGETING; GENETIC MARKER; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE MIGRATION; MEDIATOR; MEDIATOR RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TISSUE; TISSUE INJURY;

AUTOANTIGENS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; HUMANS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 33750208484     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000245728.40630.27     Document Type: Review

References (22)

1. Oppenheim JJ, Dong HF, Plotz P, et al. Autoantigens act as tissue-specific chemoattractants. J Leukoc Biol 2005; 77:854-861. Summary of both tumor and autoantigens with their corresponding receptors.
2. Howard OM, Dong HF, Su SB, et al. Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate. Blood 2005; 105:4207-4214. Reports the interaction of IRBP and S-Ag with receptors from the CXCR subfamily and shows that a chemoattractant peptide need not be lymphoproliferative.
3. Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002; 196:781-791.
4. Carlos CA, Dong HF, Howard OM, et al. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005; 175:1628-1635. First report of a tumor antigen being a chemoattractant.
5. Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9:1484-1490.
6. Maksimow M, Miiluniemi M, Marttila-Ichihara F, et al. Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor-immunity. Blood 2006; 108:1298-1305. Reports the need to remove regulatory T cells prior to dendritic cell activation by an autoantigen.
7. Decker P, Singh-Jasuja H, Haager S, et al. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol 2005; 174:3326-3334. The concept that a complex of autoantigens, nucleotides can activate dendritic cells without involving a toll-like receptor signal is reported here.
8. Kron MA, Petridis M, Haertlein M, et al. Do tissue levels of autoantigenic aminoacyl-tRNA synthetase predict clinical disease? Med Hypotheses 2005; 65:1124-1127. Reports the levels of AsnRS expression in various tissues.
9. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601. Reports the levels of HisRS expressed at rest and during different stresses in tissues.
10. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999; 284:147-151.
11. Le Y, Ye RD, Gong W, et al. Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis. FEBS J 2005; 272:769-778. Summary of current formylated methionine-leucine-phenylalanine receptor ligands and their contact domains on formyl peptide receptor-like 1.
12. Adachi T, Stafford S, Kayaba H, et al. Myosin light chain kinase mediates eosinophil chemotaxis in a mitogen-activated protein kinase-dependent manner. J Allergy Clin Immunol 2003; 111:113-116.
13. Strieter RM, Koch AE, Antony VB, et al. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994; 123:183-197.
14. Szekanecz Z, Szucs G, Szanto S, Koch AE. Chemokines in rheumatic diseases. Curr Drug Targets 2006; 7:91-102. This is a nice review of the field of chemokines and it summarizes the current status of chemokine antagonists.
15. De Paepe B, De Keyzer K, Martin JJ, De Bleecker JL. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol (Berl) 2005; 109:576-582. Reports levels of chemokines and chemokine receptors in myopathies.
16. De Paepe B, De Bleecker JL. Beta-chemokine receptor expression in idiopathic inflammatory myopathies. Muscle Nerve 2005; 31:621-627. Continues the earlier study showing the status of the few receptors not previously reported.
17. Civatte M, Bartoli C, Schleinitz N, et al. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005; 31:70-79.
18. Houman H, Hamzaoui A, Ben Ghorbal I, et al. Abnormal expression of chemokine receptors in Behcet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun 2004; 23:267-273.
19. Wells TN, Power CA, Shaw JP, Proudfoot AE. Chemokine blockers: therapeutics in the making? Trends Pharmacol Sci 2006; 27:41-47. Critical review of the status of chemokine antagonists.
20. van Berkel V, Barrett J, Tiffany HL, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000; 74:6741-6747.
21. Jensen KK, Chen SC, Hipkin RW, et al. Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J Virol 2003; 77:624-630.
22. Stanford M, Whittall T, Bergmeier LA, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 2004; 137:201-208.